Kiss, Szilárd

Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration

Grishanin, R., Vuillemenot, B., Sharma, P., Keravala, A., Greengard, J., Gelfman, C., Blumenkrantz, M., Lawrence, M., Hu, W., Kiss, S., et al. (2019) · Molecular Therapy

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 127

Review of gene therapies for age-related macular degeneration

Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye

Retinal Development and DisordersRetinal Diseases and Treatments

Cited by 119

Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration

Holekamp, N. M., Liu, Y., Yeh, W.-S., Chia, Y., Kiss, S., Almony, A., & Kowalski, J. W. (2014) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 88

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study

Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 76

Comprehensive preclinical assessment of ADVM-022, an intravitreal anti-VEGF gene therapy for the treatment of neovascular AMD and diabetic macular edema

Gelfman, C. M., Grishanin, R., Bender, K. O., Nguyen, A., Greengard, J., Sharma, P., Nieves, J., Kiss, S., & Gasmi, M. (2021) · Journal of Ocular Pharmacology and Therapeutics

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 55

Long-term safety evaluation of continuous intraocular delivery of aflibercept by the intravitreal gene therapy candidate ADVM-022 in nonhuman primates

Kiss, S., Oresic Bender, K., Grishanin, R. N., Hanna, K. M., Nieves, J. D., Sharma, P., Nguyen, A. T., Rosario, R. J., Greengard, J. S., Gelfman, C. M., et al. (2021) · Translational Vision Science & Technology

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 36

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Kiss, S., Grishanin, R., Nguyen, A., Rosario, R., Greengard, J. S., Nieves, J., Gelfman, C. M., & Gasmi, M. (2020) · Molecular Therapy - Methods & Clinical Development

Retinal Diseases and TreatmentsVirus-based gene therapy research

Cited by 29

Advancements in ocular gene therapy delivery: vectors and subretinal, intravitreal, and suprachoroidal techniques

Kovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy

Retinal Development and DisordersVirus-based gene therapy research

Cited by 20

Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration

Gyenes, A., István, L., Benyó, F., Papp, A., Resch, M., Sándor, N., Józsi, M., Nagy, Z. Z., Kovács, I., & Kiss, S. (2023) · BMC Ophthalmology

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 9

Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes

Poulsen, K., Hanna, K., Nieves, J., Nguyen, N., Sharma, P., Grishanin, R., Corbau, R., & Kiss, S. (2025) · Molecular Therapy Methods & Clinical Development

Virus-based gene therapy researchRetinal Diseases and Treatments

Cited by 8